Stephen Devereux
Overview
Explore the profile of Stephen Devereux including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Robbe P, Ridout K, Vavoulis D, Dreau H, Kinnersley B, Denny N, et al.
Nat Genet
. 2022 Nov;
54(11):1675-1689.
PMID: 36333502
The value of genome-wide over targeted driver analyses for predicting clinical outcomes of cancer patients is debated. Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled...
2.
Cuthill K, Zhang Y, Pepper A, Boelen L, Coulter E, Asquith B, et al.
Leukemia
. 2022 Jul;
36(9):2233-2241.
PMID: 35902732
Pathogenesis in chronic lymphocytic leukemia (CLL) is strongly linked to the potential for leukemic cells to migrate to and proliferate within lymph-nodes. Previous in vivo studies suggest that all leukemic...
3.
Byrd J, Woyach J, Furman R, Martin P, OBrien S, Brown J, et al.
Blood
. 2021 Mar;
137(24):3327-3338.
PMID: 33786588
Acalabrutinib has demonstrated significant efficacy and safety in relapsed chronic lymphocytic leukemia (CLL). Efficacy and safety of acalabrutinib monotherapy were evaluated in a treatment-naive CLL cohort of a single-arm phase...
4.
Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, et al.
Blood
. 2021 Jan;
137(22):3064-3078.
PMID: 33512408
Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9)...
5.
Devereux S, Bene C, Hoddinott J
Food Secur
. 2020 Aug;
12(4):769-772.
PMID: 32837651
COVID-19 undermines food security both directly, by disrupting food systems, and indirectly, through the impacts of lockdowns on household incomes and physical access to food. COVID-19 and responses to the...
6.
Byrd J, Wierda W, Schuh A, Devereux S, Chaves J, Brown J, et al.
Blood
. 2019 Dec;
135(15):1204-1213.
PMID: 31876911
Therapeutic targeting of Bruton tyrosine kinase (BTK) has dramatically improved survival outcomes for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Acalabrutinib is an oral, highly selective BTK inhibitor...
7.
Burger J, Barr P, Robak T, Owen C, Ghia P, Tedeschi A, et al.
Leukemia
. 2019 Oct;
34(3):787-798.
PMID: 31628428
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to...
8.
Townsend W, Pasikowska M, Yallop D, Phillips E, Patten P, Salisbury J, et al.
Haematologica
. 2019 Sep;
105(6):1593-1603.
PMID: 31537685
CD4 T-follicular helper cells are essential for the survival, proliferation, and differentiation of germinal center B cells and have been implicated in the pathogenesis of follicular lymphoma (FL). To further...
9.
Hillmen P, Rawstron A, Brock K, Munoz-Vicente S, Yates F, Bishop R, et al.
J Clin Oncol
. 2019 Jul;
37(30):2722-2729.
PMID: 31295041
Purpose: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and...
10.
Devereux S, Tavener-Smith L
Nutrients
. 2019 Jul;
11(7).
PMID: 31284521
Very little is known about seasonal hunger in South Africa, or about the food security and nutritional status of farm workers. This article identifies a pathway to seasonal hunger-through intra-annual...